Closing out their discussion on mobocertinib data and the EXCLAIM cohort, experts share hope for the future management of the EGFR exon 20 insertion–positive mNSCLC.
A brief review of biomarker testing in metastatic non–small cell lung cancer to identify alterations such as the EGFR exon 20 insertion.
In the context of mobocertinib clinical data, experts consider factors that help them select therapy and manage therapy for patients with EGFR exon 20 insertion–positive mNSCLC.
Focused discussion on the safety profile of mobocertinib in platinum-pretreated EGFR exon 20 insertion–positive mNSCLC given data from the EXCLAIM cohort.
In an interview with ONCOLOGY®, Evan B. Bryson, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of amivantamab as therapy for patients with non–small cell lung cancer.
Shared insight on efficacy data with mobocertinib from the EXCLAIM cohort of patients with platinum-pretreated EGFR exon 20 insertion–positive mNSCLC.
Expert oncologists review data from the EXCLAIM cohort, which analyzed mobocertinib use in platinum-pretreated patients with EGFR exon 20 insertion–positive mNSCLC.
The TERAVOLT study identified 7 factors associated with increased mortality risk for patients with thoracic malignancies who have contracted COVID-19.
In an interview with ONCOLOGY®, Megan May, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of mobocertinib as therapy for patients with lung cancer.
The 2021 United States Preventive Services Task Force lung cancer screening criteria changes successfully reduced racial disparities in eligibility by broadening screening eligibility criteria.